69 related articles for article (PubMed ID: 9359008)
1. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
[TBL] [Abstract][Full Text] [Related]
2. Comparison of platelet antibody screen, crossmatching and HLA antibody testing in patients refractory to platelet transfusions.
Chapman JM; Wendt L; Knudson CM
Transfus Apher Sci; 2023 Jun; 62(3):103622. PubMed ID: 36535829
[TBL] [Abstract][Full Text] [Related]
3. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice.
Jackman RP; Darst O; Gaillard B; Tran JQ; Tomayko MM; Muench MO
Front Immunol; 2023; 14():1281123. PubMed ID: 38090570
[TBL] [Abstract][Full Text] [Related]
4. The importance of ABO in platelet refractoriness, an often overlooked option.
Gammon R; Mo A
Br J Haematol; 2024 May; 204(5):1602-1604. PubMed ID: 38544441
[TBL] [Abstract][Full Text] [Related]
5. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice.
Tran JQ; Muench MO; Gaillard B; Darst O; Tomayko MM; Jackman RP
Front Immunol; 2023; 14():1281130. PubMed ID: 38146372
[TBL] [Abstract][Full Text] [Related]
6. Engineered platelets-based drug delivery platform for targeted thrombolysis.
Wang S; Wang R; Meng N; Lu L; Wang J; Zhou J; Lu J; Xu Q; Xie C; Zhan C; Li Y; Yu Y; Lu W; Liu M
Acta Pharm Sin B; 2022 Apr; 12(4):2000-2013. PubMed ID: 35847517
[TBL] [Abstract][Full Text] [Related]
7. Platelet kinetics after slow versus standard transfusions: a pilot study.
Habibi A; Esfandbod M; Ghafari MH; Khashayar P; Najafi A; Moharari RS
Ups J Med Sci; 2011 Aug; 116(3):212-5. PubMed ID: 21679106
[TBL] [Abstract][Full Text] [Related]
8. Alloimmune refractoriness to platelet transfusions.
Sandler SG
Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
Sandler SG
Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
[TBL] [Abstract][Full Text] [Related]
10. Management of the Platelet Refractory Patient.
Forest SK; Hod EA
Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
[TBL] [Abstract][Full Text] [Related]
11. Management of patients refractory to platelet transfusion.
Chockalingam P; Sacher RA
J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
[TBL] [Abstract][Full Text] [Related]
12. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
